SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
SciSparc (Nasdaq: SPRC) announced that its joint venture MitoCareX Bio is expanding into pancreatic cancer research following positive initial in-vitro results. MitoCareX, which develops cancer therapeutics targeting the mitochondrial SLC25 protein family, has successfully identified potential anti-cancer treatments through its computational drug discovery platform that screened millions of small molecules.
The expansion adds pancreatic cancer to MitoCareX's existing research on non-small cell lung cancer. The company is also developing an AI model to analyze virtual data for discovering novel anti-cancer scaffolds. The announcement highlights that pancreatic cancer, with just a 12% five-year survival rate as of 2023, is the third leading cause of cancer-related deaths in the United States, representing a significant unmet medical need.
SciSparc (Nasdaq: SPRC) ha annunciato che la sua joint venture MitoCareX Bio sta ampliando le sue ricerche sul cancro pancreatico dopo risultati iniziali in vitro positivi. MitoCareX, che sviluppa terapie antitumorali mirate alla famiglia di proteine SLC25 mitocondriali, ha identificato con successo potenziali trattamenti anti-cancro attraverso la sua piattaforma di scoperta di farmaci computazionale che ha esaminato milioni di piccole molecole.
L'ampliamento aggiunge il cancro pancreatico alla ricerca già esistente di MitoCareX sul cancro polmonare a cellule non piccole. L'azienda sta inoltre sviluppando un modello di intelligenza artificiale per analizzare dati virtuali al fine di scoprire nuovi scaffold anti-cancro. L'annuncio sottolinea che il cancro pancreatico, con appena il 12% di tasso di sopravvivenza a cinque anni nel 2023, è la terza causa principale di morte per cancro negli Stati Uniti, rappresentando un significativo bisogno medico non soddisfatto.
SciSparc (Nasdaq: SPRC) anunció que su empresa conjunta MitoCareX Bio está ampliando su investigación en cáncer de páncreas después de obtener resultados in vitro iniciales positivos. MitoCareX, que desarrolla terapias contra el cáncer dirigidas a la familia de proteínas SLC25 mitocondriales, ha identificado con éxito tratamientos potenciales contra el cáncer a través de su plataforma de descubrimiento de fármacos computacional que analizó millones de pequeñas moléculas.
La expansión añade el cáncer de páncreas a la investigación existente de MitoCareX sobre cáncer de pulmón de células no pequeñas. La empresa también está desarrollando un modelo de inteligencia artificial para analizar datos virtuales con el fin de descubrir nuevos andamios anti-cáncer. El anuncio destaca que el cáncer de páncreas, con solo un 12% de tasa de supervivencia a cinco años en 2023, es la tercera causa principal de muertes relacionadas con el cáncer en Estados Unidos, representando una necesidad médica insatisfecha significativa.
SciSparc (Nasdaq: SPRC)는 공동 벤처 MitoCareX Bio가 긍정적인 초기 인비트로 결과를 바탕으로 췌장암 연구를 확대하고 있다고 발표했습니다. MitoCareX는 미토콘드리아 SLC25 단백질 가족을 목표로 하는 암 치료제를 개발하며, 수백만 개의 작은 분자를 스크리닝한 컴퓨터 약물 발견 플랫폼을 통해 잠재적인 항암 치료제를 성공적으로 식별했습니다.
이번 확대는 MitoCareX의 비소세포 폐암에 대한 기존 연구에 췌장암을 추가하는 것입니다. 이 회사는 또한 새로운 항암 스캐폴드 발견을 위한 가상 데이터를 분석하는 AI 모델을 개발하고 있습니다. 발표된 내용에 따르면 췌장암은 2023년 기준으로 5년 생존율이 단 12%에 불과하며, 미국에서 암 관련 사망의 세 번째 주요 원인이 되어 큰 의학적 필요가 존재합니다.
SciSparc (Nasdaq: SPRC) a annoncé que sa coentreprise MitoCareX Bio élargit ses recherches sur le cancer du pancréas suite à des résultats initiaux positifs in vitro. MitoCareX, qui développe des thérapies anticancéreuses ciblant la famille de protéines SLC25 mitochondriales, a réussi à identifier des traitements anticancéreux potentiels grâce à sa plateforme de découverte de médicaments informatique qui a passé au crible des millions de petites molécules.
Cette expansion ajoute le cancer du pancréas à la recherche existante de MitoCareX sur le cancer du poumon non à petites cellules. L'entreprise développe également un modèle d'IA pour analyser des données virtuelles afin de découvrir de nouveaux échafaudages anticancéreux. L'annonce souligne que le cancer du pancréas, avec seulement 12 % de taux de survie à cinq ans en 2023, est la troisième cause de décès liés au cancer aux États-Unis, représentant un besoin médical non satisfait significatif.
SciSparc (Nasdaq: SPRC) hat angekündigt, dass sein Joint Venture MitoCareX Bio in die Forschung zu Bauchspeicheldrüsenkrebs expandiert, nachdem positive erste In-vitro-Ergebnisse vorliegen. MitoCareX, das onkologische Therapeutika entwickelt, die auf die mitochondrialen SLC25-Proteinfamilie abzielen, hat erfolgreich potenzielle Krebsbehandlungen über seine computergestützte Arzneimittelentdeckungsplattform identifiziert, die Millionen von kleinen Molekülen gescreent hat.
Die Erweiterung fügt dem bestehenden Forschungsbereich von MitoCareX zu nicht kleinzelligem Lungenkrebs nun auch Bauchspeicheldrüsenkrebs hinzu. Das Unternehmen entwickelt außerdem ein KI-Modell zur Analyse virtueller Daten zur Entdeckung neuartiger Anti-Krebs-Skaffold. Die Ankündigung hebt hervor, dass Bauchspeicheldrüsenkrebs, der im Jahr 2023 eine Fünf-Jahres-Überlebensrate von nur 12% aufweist, die dritthäufigste Ursache für krebsbedingte Todesfälle in den USA ist, was einen erheblichen unerfüllten medizinischen Bedarf darstellt.
- Successful identification of anti-cancer compounds through computational screening
- Expansion of therapeutic pipeline to include pancreatic cancer
- Positive initial in-vitro results in pancreatic cancer cell lines
- Development of AI-powered drug discovery platform
- None.
Insights
The expansion into pancreatic cancer research represents a strategic pivot that could significantly impact SciSparc's market position. MitoCareX's approach targeting the mitochondrial SLC25 protein family is particularly noteworthy as mitochondrial metabolism plays a important role in pancreatic cancer's aggressive nature. The initial in-vitro results, while preliminary, are promising in a field where new therapeutic approaches are desperately needed.
The computational drug discovery platform's ability to screen millions of molecules efficiently could accelerate the development timeline and reduce costs significantly compared to traditional methods. The integration of AI for predictive modeling adds another layer of sophistication that could enhance the probability of identifying effective compounds. However, it's important to note that the path from in-vitro success to clinical validation is long and complex, with historically low success rates in pancreatic cancer drug development.
The market opportunity is substantial - pancreatic cancer therapeutics market is projected to grow significantly, driven by the high mortality rate and treatment options. For a company with a market cap of
This development positions SPRC to potentially capture value in the highly lucrative pancreatic cancer market. The company's dual approach of computational screening and traditional in-vitro validation presents a capital-efficient research strategy that could accelerate the typical drug discovery timeline. The AI component is particularly valuable, as it could lead to additional intellectual property and partnering opportunities.
The focus on the SLC25 protein family is strategically sound, as mitochondrial targets represent an emerging area in oncology with less competition than traditional approaches. The market implications are significant - successful early-stage results could attract partnership interest from larger pharmaceutical companies, especially given the high unmet need in pancreatic cancer treatment. Current market leaders in pancreatic cancer therapeutics typically trade at premium valuations, suggesting substantial upside potential if clinical development progresses successfully.
TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.
MitoCareX, which focuses on drug discovery and the development of cancer therapeutics targeting the mitochondrial SLC25 protein family, recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments.
By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures discovered out of millions of them that were virtually screened the addition of pancreatic cancer to its existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions.
Additionally, MitoCareX continues its efforts to create a predictive artificial intelligence (AI) model, utilizing the extensive virtual data generated during its discovery processes. This model is designed to efficiently navigate broader chemical spaces, with the goal of uncovering more novel anti-cancer scaffolds targeting the SLC25 protein family.
Pancreatic cancer remains one of the most aggressive and difficult-to-treat cancers, with a significant unmet medical need. According to the American Cancer Society, the 5-year survival rate for pancreatic cancer is just
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses MitoCareX’s encouraging initial in-vitro results, that the addition of pancreatic cancer to MitoCareX’s existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions, potential benefits and advantages of MitoCareX’s predictive AI model and significant unmet need for pancreatic cancer. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
FAQ
What are the latest developments in SPRC's pancreatic cancer research?
How is SPRC using AI in its cancer drug development?
What is the current focus of SPRC's cancer research pipeline?
What is the significance of SPRC's expansion into pancreatic cancer research?
